Summary by Moomoo AI
On February 2, 2024, NexImmune, Inc., a biotechnology company listed on Nasdaq under the ticker NEXI, announced a registered direct offering and a concurrent private placement expected to raise approximately $3.67 million. The offering, priced at-the-market under Nasdaq rules, involves the sale of 117,000 shares of common stock at $12.05 per share and pre-funded warrants exercisable for up to 187,731 shares at $12.049 per warrant. Additionally, unregistered warrants to purchase up to 304,731 shares of common stock at $12.05 per share are being offered in the private placement. The closing of the offerings is anticipated on February 6, 2024, subject to customary conditions. The company has agreed to certain restrictions on stock issuance for 20 days post-closing. H.C. Wainwright & Co. is acting as the exclusive placement agent...Show More